Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions

Click Here To Save Now

About Us
Programs
Resources
Find a Provider
- COPE Educational Programs
Shop
Donate
- Privacy Policy
- Donor Bill of Rights

Dec 18, 2023

Seeing AI- Now on Android

Now on Android

One Day Only- Matters of Vision! 2025 Denver-Aurora, CO

Apr 17, 2025

Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy

Apr 6, 2025

Long-Term Visual Outcomes of Patients With nAMD Treated With Anti-VEGF Therapy Lost to Follow-Up

Newsletter Sign-up

Name**
Email**
CAPTCHA
Phone
This field is for validation purposes and should be left unchanged.

5969 Cattleridge Boulevard, Suite 100
Sarasota, Florida 34232

(855) 962-2852 info@macularhope.org

https://www.facebook.com/macularhope/ https://twitter.com/macularhope?lang=en

The Macular Degeneration Association, Inc. is a registered 501(c)(3) non-profit corporation. A copy of the official registration and financial information may be obtained from the division of consumer services by calling toll-free within the state (1-800-help-fla) or on the consumer services website www.800helpfla.com. Registration does not imply endorsement, approval, or recommendation by the state.

| Privacy & Terms

Seeing AI- Now on Android

Leave a Reply Cancel reply

One Day Only- Matters of Vision! 2025 Denver-Aurora, CO

Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for nonproliferative diabetic retinopathy

Long-Term Visual Outcomes of Patients With nAMD Treated With Anti-VEGF Therapy Lost to Follow-Up